Prediction of breast cancer prognosis by gene expression profile of TP53 status-Reference-Cited by-同舟云学术

Prediction of breast cancer prognosis by gene expression profile of TP53 status

Published:2008-02 Issue:2 Volume:99 Page:324-332
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Takahashi Shin,Moriya Takuya,Ishida Takanori,Shibata Hiroyuki,Sasano Hironobu,Ohuchi Noriaki,Ishioka Chikashi

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2007.00691.x/fullpdf

Reference25 articles.

1. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

2. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

3. 3International Agency for Research on Cancer, and IARC (). IARCTp53mutation database . Database Downlords: Dataset of Somatic Mutation. [Cited 28 July 2005] Available from URL: http://www-p53.iarc.fr/Somatic.html.

4. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

5. Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts;Translational Oncology;2024-10

2. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile;Breast Cancer Research;2023-05-09

3. TP53Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer;Anticancer Research;2023-03-27

4. TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease;Breast Cancer: Basic and Clinical Research;2023-01

5. The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer;Anticancer Research;2022-04-30